Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.

Etanercept in Adult Dermatomyositis

Principal Investigator:

A. Amato & Muscle Study Group (9 sites)

Study Design:

Randomized, double-blind, placebo-controlled trial of Etanercept (all patients will initially be started on prednisone)

Types & Number of IIM Studied:

Adult dermatomyositis (n = 16)

Entry Criteria:

Definite Dermatomyositis

IMACS Core Set Measures Included:

Physician and Patient Global Activity Assessments, Manual Muscle Testing, Health Assessment Questionnaire

Other Measures Included:

Cutaneous Assessment Disease Activity Severity Index (CDASI), pulmonary function testing, electrocardiogram, MVICT, magnetic resonance imaging, skin biopsy; DNA microarrays on muscle, skin, and peripheral white blood cells

Primary Outcome:

Cumulative dose of prednisone; Number of treatment failures; Responsiveness of IMACS outcome variables

Study Duration:

12 months


Enrollment Completed


Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis., Ann Neurol, 2011 Sep;70(3):427-36. [Abstract Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis., Ann Neurol, 2011 Sep;70(3):427-36.]


Anthony A. Amato, M.D.
Professor of Neurology
Brigham and Women's Hospital
Neurology, ASB 1-2
75 Francis St
Boston, MA 02115
Tel 617-732-5436
Fax 617-730-2885
to Top